Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 4/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 2/20 | 0.38 |
| ▸ | TGM1 | P22735 | 2/20 | 0.38 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 5/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22460891 | 1.00 | TGM2 (0.41) | TGM2CCNKCCNA2CDK2CDK7 | |
| SCHEMBL24490303 | 0.83 | KIF11 (0.54) | ESR1ESR2KIF11SLC6A2SLC6A4 | |
| SCHEMBL22460923 | 0.83 | KIF11 (0.54) | ESR1ESR2KIF11SLC6A2SLC6A4 | |
| SCHEMBL22461197 | 0.83 | SLC6A2 (0.52) | ESR1ESR2KIF11SLC6A2SLC6A4 | |
| SCHEMBL22461286 | 0.83 | SLC6A2 (0.52) | ESR1ESR2KIF11SLC6A2SLC6A4 | |
| SCHEMBL24490249 | 0.80 | KIF11 (0.41) | ESR1ESR2KIF11SLC6A2SLC6A4 | |
| SCHEMBL22460902 | 0.80 | KIF11 (0.53) | KIF11SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24490248 | 0.80 | KIF11 (0.41) | ESR1ESR2KIF11SLC6A2SLC6A4 | |
| SCHEMBL22460919 | 0.80 | KIF11 (0.53) | KIF11SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24490161 | 0.76 | ESR1 (0.44) | ESR1ESR2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086194-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | Suvalent Therapeutics, Inc. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | CIT THERAPEUTICS LLC | 2022-06-09 | — | — | US | disclosed |
| WO-2020191151-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177488-A1 | SUMO INHIBITOR COMPOUNDS AND USES THEREOF | SUMO1, SUMO2, SUMO3 | TGM2 2181/4885CCNK 1430/4885CCNA2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.